Emmaus Life has announced that it has a Medicaid Drug Rebate agreement with the Centers for Medicare and Medicaid Services which allow coverage for Endari.
Endari is a recently released treatment by Emmaus that reduces the symptoms of sickle cell disease. Endari is the first treatment approved by the FDA for pediatric patients five years of age and older with the disease, and the first treatment approved by the FDA in nearly 20 years for adult patients.
All states currently provide coverage for outpatient prescription drugs under such agreements to all eligible Medicaid enrollees within their state Medicaid programs.
Emmaus Life Sciences, Inc. works on discovering, developing and commercialization of innovative treatments and therapies for rare diseases.